VEMLIDY's Impact on Chronic Hepatitis B Treatment Landscape Through 2032 Dublin, May 03, 2024 (GLOBE NEWSWIRE) -- The "VEMLIDY Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report addresses crucial...

Entecavir for Chronic Hepatitis B in 7MM: Market Size, Forecasts, and Emerging Insights 2019-2023 & 2024-2032 Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Entecavir Market Size, Forecast, and Market Insight - 2032" report has been added to ResearchAndMarkets.com's offering.A thorough market analysis on...

BRII-835 + BRII-179 for Chronic Hepatitis B in 7MM: Market Size, Forecast, and Emerging Insights 2019-2032 Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering."BRII-835 +...

Bepirovirsen for Chronic Hepatitis B Drug Pipeline Report 2024: 7MM Market Size, Forecast, and Emerging Insights 2019-2032 Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Bepirovirsen Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...

OnCore Biopharma Licenses Second-Generation Cyclophilin Inhibitors From NeuroVive for the Treatment of Chronic HBV Infection OnCore Secures Exclusive Worldwide Rights to NVP018 NVP018 Will Complement OnCore's Existing Pipeline Directed at Achieving All-Oral Cure for HBV DOYLESTOWN, Pa., Sept. 9, 2014 (GLOBE NEWSWIRE)...